AP SA 02
Alternative Names: AP-SA-02Latest Information Update: 26 Aug 2025
At a glance
- Originator Armata Pharmaceuticals
- Class Anti-infectives; Antibacterials; Bacteriophages
- Mechanism of Action Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Staphylococcal infections
- Preclinical Bone and joint infections
- No development reported Bronchiectasis
Most Recent Events
- 12 Aug 2025 Armata plans to hold an end-of-Phase 2 meeting with the US FDA in the second half of this year to align on a superiority trial design
- 12 Aug 2025 Armata Pharmaceuticals plans a phase III pivotal trial for Staphylococcus infections in 2026
- 20 May 2025 Efficacy and adverse events data from a phase I/II diSArm trial in Staphylococcal infections released by Armata Pharmaceuticals